Bayer Shering Pharma Applies For iPS Patent With Japan Patent Office
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bayer Shering Pharma AG has submitted patent applications for its induced pluripotent stem cell manufacturing method with the Japan Patent Office, the first foreign entity to seek intellectual property rights protection for an iPS method after one filed by Kyoto University Professor Shinya Yamanaka, according to Bayer's patent filing released by JPO Dec. 25, 2008
You may also be interested in...
Bayer Yakuhin To Sell Kobe Research Lab (Japan)
Bayer Yakuhin Ltd., a Japanese subsidiary of German pharmaceutical firm Bayer Schering Pharma AG, plans to close a Kobe research laboratory before the end of the year and sell it. The move is part of Bayer's effort to streamline operations after it acquired last year German drugmaker Schering AG and in July consolidated the two firms' Japanese units. The lab has been involved in basic research, including stem cell cultivation, achieving some breakthroughs. Following the merger, however, Bayer Schering decided to concentrate research on cancer, heart disease, gynecological disorders and diagnostic imaging drugs. (Click here for more - May Require Paid Subscription
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).